116 related articles for article (PubMed ID: 12590242)
1. Candesartan cilexetil-induced severe hepatotoxicity.
Basile G; Villari D; Gangemi S; Ferrara T; Accetta MG; Nicita-Mauro V
J Clin Gastroenterol; 2003 Mar; 36(3):273-5. PubMed ID: 12590242
[TBL] [Abstract][Full Text] [Related]
2. Erythema multiforme associated with candesartan cilexetil.
Ejaz AA; Walsh JS; Wasiluk A
South Med J; 2004 Jun; 97(6):614-5. PubMed ID: 15255435
[TBL] [Abstract][Full Text] [Related]
3. [Candesartan Cilexetil (Atacand) induced prolonged severe cholestasis improved by extracorporeal albumin dialysis].
Sturm N; Hilleret MN; Dreyfus T; Barnoud D; Leroy V; Zarski JP
Gastroenterol Clin Biol; 2005 Dec; 29(12):1299-301. PubMed ID: 16518295
[No Abstract] [Full Text] [Related]
4. Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia
.
Katsube Y; Hira D; Tsujimoto M; Koide H; Minegaki T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):328-336. PubMed ID: 29792394
[TBL] [Abstract][Full Text] [Related]
5. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
Oparil S
Am J Cardiol; 1999 Nov; 84(10A):35S-41S. PubMed ID: 10588093
[TBL] [Abstract][Full Text] [Related]
6. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
Neldam S; Forsén B;
Drugs Aging; 2001; 18(3):225-32. PubMed ID: 11302289
[TBL] [Abstract][Full Text] [Related]
9. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.
Belcher G; Hübner R; George M; Elmfeldt D; Lunde H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S85-9. PubMed ID: 9331017
[TBL] [Abstract][Full Text] [Related]
10. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
Oparil S; Levine JH; Zuschke CA; Gradman AH; Ripley E; Jones DW; Hardison JD; Cushing DJ; Prasad R; Michelson EL
Am J Cardiol; 1999 Aug; 84(3):289-93. PubMed ID: 10496437
[TBL] [Abstract][Full Text] [Related]
11. Drug points: prolonged cholestasis associated with irbesartan.
Hariraj R; Stoner E; Jader S; Preston DM
BMJ; 2000 Sep; 321(7260):547. PubMed ID: 10968816
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
Takahara M; Shiraiwa T; Shindo M; Arai A; Kusuda Y; Katakami N; Kaneto H; Matsuoka TA; Shimomura I
Hypertens Res; 2014 Sep; 37(9):852-7. PubMed ID: 24739538
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
14. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
McInnes GT; O'Kane KP; Jonker J; Roth J
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
17. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
[TBL] [Abstract][Full Text] [Related]
18. Candesartan cilexetil induced pustular psoriasis.
Kawamura A; Ochiai T
Eur J Dermatol; 2003; 13(4):406-7. PubMed ID: 12948927
[TBL] [Abstract][Full Text] [Related]
19. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
